The Experts below are selected from a list of 29112 Experts worldwide ranked by ideXlab platform
Florian R. Greten - One of the best experts on this subject based on the ideXlab platform.
-
The Gastrointestinal Tumor Microenvironment
Gastroenterology, 2013Co-Authors: Michael Quante, Julia Varga, Timothy C. Wang, Florian R. GretenAbstract:Over the past decade, the microenvironment of Gastrointestinal Tumors has gained increasing attention because it is required for Tumor initiation, progression, and metastasis. The Tumor microenvironment has many components and has been recognized as one of the major hallmarks of epithelial cancers. Although therapeutic strategies for Gastrointestinal cancer have previously focused on the epithelial cell compartment, there is increasing interest in reagents that alter the microenvironment, based on reported interactions among Gastrointestinal epithelial, stromal, and immune cells during Gastrointestinal carcinogenesis. We review the different cellular components of the Gastrointestinal Tumor microenvironment and their functions in carcinogenesis and discuss how improving our understanding of the complex stromal network could lead to new therapeutic strategies.
Hans Scherübl - One of the best experts on this subject based on the ideXlab platform.
-
Rising concentrations of IFNγ for 5 days led to a time- and dose-dependent growth inhibition of neuroendocrine Gastrointestinal Tumor cells, as measured by crystal violet staining
2011Co-Authors: Michael Höpfner, Gudrun Ahnert-hilger, Andreas P Sutter, Alexander Huether, Hans ScherüblAbstract:Copyright information:Taken from "A novel approach in the treatment of neuroendocrine Gastrointestinal Tumors: Additive antiproliferative effects of interferon-γ and meta-iodobenzylguanidine"BMC Cancer 2004;4():23-23.Published online 21 May 2004PMCID:PMC442128.Copyright © 2004 Höpfner et al; licensee BioMed Central Ltd. This is an Open Access article: verbatim copying and redistribution of this article are permitted in all media for any purpose, provided this notice is preserved along with the article's original URL. The growth of BON Tumor cells was inhibited with an ICvalue of 135 ± 10 U/ml (). STC-1 cells displayed an ICvalue of about 100 U/ml (95 ± 15 U/ml) (). Data are given as percentage of untreated controls (means ± SEM of 4 experiments). *, statistical significance (< 0.05) compared to untreated controls
-
Meta-iodobenzylguanidine induces growth inhibition and apoptosis of neuroendocrine Gastrointestinal Tumor cells
International journal of cancer, 2002Co-Authors: Michael Höpfner, A P Sutter, Nikolai I. Beck, B Barthel, Kerstin Maaser, Maria C. Jockers-scherübl, Martin Zeitz, Hans ScherüblAbstract:Neuroendocrine Gastrointestinal Tumors take up, decarboxylate and store large amounts of monoamines. Radioactive-labeled monoamines like the norepinephrine analogue meta-iodobenzylguanidine (MIBG) have been used for the imaging of neuroendocrine Tumors for many years. MIBG is selectively taken up via norepinephrine transporters (NETs) localized in the plasma membrane of neuroendocrine Gastrointestinal Tumor cells and thereby offers the possibility for specific and innovative therapeutic approaches. We investigated the antiproliferative, cytotoxic, cell cycle-arresting and apoptosis-inducing effects of MIBG in the neuroendocrine Gastrointestinal Tumor cell line STC-1 and for control in the nonneuroendocrine colorectal cancer cell line HT-29. RT-PCR revealed the expression of NET in STC-1 but not in HT-29 cells. MIBG dose-dependently induced cytotoxicity and growth inhibition of STC-1 cells. It potently induced apoptosis in STC-1 cells as assessed by changes in the mitochondrial membrane potential, activation of caspase-3 and DNA fragmentation. Moreover, MIBG altered the expression of several genes involved in proliferation, apoptosis and stress responses as shown by cDNA arrays. In contrast, neither cytotoxicity, nor growth inhibition nor induction of apoptosis were detected in response to MIBG in the NET-deficient colorectal cancer cell line HT-29. Our data show that MIBG induces growth inhibition and apoptosis in neuroendocrine Gastrointestinal Tumor cells. MIBG did not arrest the cell cycle in either cell line. Thus, monoamine transporters in the plasma membrane of neuroendocrine Gastrointestinal Tumor cells are promising targets for innovative and specific treatment strategies of these Tumors. © 2002 Wiley-Liss, Inc.
-
Expression of dopamine receptors and transporter in neuroendocrine Gastrointestinal Tumor cells.
Life sciences, 2002Co-Authors: K. Lemmer, Michael Höpfner, Maria C. Jockers-scherübl, Martin Zeitz, Gudrun Ahnert-hilger, S Hoegerle, S. Faiss, Patricia Grabowski, Ernst-otto Riecken, Hans ScherüblAbstract:Abstract C-11- or F-18-DOPA positron emission tomography (DOPA PET) is a new sensitive imaging technique for small neuroendocrine Gastrointestinal Tumors which evaluates the decarboxylase activity. To further characterize the dopaminergic system in neuroendocrine Gastrointestinal Tumor cells, we investigated the expression of both dopamine receptors and the transmembrane dopamine transporter (DAT) in the human neuroendocrine pancreatic cell line BON and in the neuroendocrine gut cell line STC-1. Both BON and STC-1 cells expressed mRNA of the dopamine receptors D2–D5 and DAT. mRNA of the dopamine receptor D1 was detected in BON cells only. Both in BON and STC-1 cells, expression of D2 and D5 receptors and DAT was also demonstrated immunocytochemically. For functional receptor characterization intracellular cAMP levels ([cAMP]i) were determined. Whereas in STC-1 cells dopamine and the D1-like (D1/D5) receptor agonist SKF 38393 increased [cAMP]i, [cAMP]i was decreased by dopamine or the D2-like (D2–D4) receptor agonist quinpirole in BON cells. Functional DAT activity was, however, not detected in either cell line. The presence of both dopamine receptors and of the DAT suggests an autocrine and/or paracrine function of dopamine in neuroendocrine Gastrointestinal Tumor cells. Yet neither the transmembrane dopamine transporter nor dopamine receptors are likely to contribute to positive DOPA PET imaging of neuroendocrine Gastrointestinal Tumors. However, these molecules may be of diagnostic importance when applying other dopaminergic system tracers.
Jiang Min - One of the best experts on this subject based on the ideXlab platform.
-
Dynamic observation of the cell immunity function of the patients with Gastrointestinal Tumor at III stage
Journal of Modern Oncology, 2007Co-Authors: Jiang MinAbstract:Objective:To evaluate the cell immunity function of the patients with Gastrointestinal Tumor at Ⅲ stage.Methods:Twenty five patients of Gastrointestinal Tumor at Ⅲ were enrolled in the study.Peripheral blood NK cell activity,CD3+,CD4+,CD8+ and CD4+/CD8+wrer determined before and 1,2,3,4 week after the operation.And compare with normal control group.Results:Compared with the control group,before operation,the Gastrointestinal Tumor patients' NK cell activity,CD3+,and CD4+ decreased distinctly whereas the CD8+ increased,and consequently the ratio CD4+/CD8+ is diminished(P0.01);Two weeks after the operation,the immunity function of the patients was restrained,and three weeks after the operation,the immunity function was better;four weeks after the operation the immunity function of the patients recovered to normal level.If recrudescence or metastasis occred,the immunity function of the cells may be again restrained.Conclusion:There exist some relation between the immunity system and Gastrointestinal Tumor at Ⅲ stage.
Michael Quante - One of the best experts on this subject based on the ideXlab platform.
-
The Gastrointestinal Tumor Microenvironment
Gastroenterology, 2013Co-Authors: Michael Quante, Julia Varga, Timothy C. Wang, Florian R. GretenAbstract:Over the past decade, the microenvironment of Gastrointestinal Tumors has gained increasing attention because it is required for Tumor initiation, progression, and metastasis. The Tumor microenvironment has many components and has been recognized as one of the major hallmarks of epithelial cancers. Although therapeutic strategies for Gastrointestinal cancer have previously focused on the epithelial cell compartment, there is increasing interest in reagents that alter the microenvironment, based on reported interactions among Gastrointestinal epithelial, stromal, and immune cells during Gastrointestinal carcinogenesis. We review the different cellular components of the Gastrointestinal Tumor microenvironment and their functions in carcinogenesis and discuss how improving our understanding of the complex stromal network could lead to new therapeutic strategies.
Geert Kazemier - One of the best experts on this subject based on the ideXlab platform.
-
Advanced analytics and artificial intelligence in Gastrointestinal cancer: a systematic review of radiomics predicting response to treatment
European Journal of Nuclear Medicine and Molecular Imaging, 2020Co-Authors: Nina J. Wesdorp, Tessa Hellingman, Elise P. Jansma, Jan-hein T. M. Waesberghe, Ronald Boellaard, Cornelis J. A. Punt, Joost Huiskens, Geert KazemierAbstract:Purpose Advanced medical image analytics is increasingly used to predict clinical outcome in patients diagnosed with Gastrointestinal Tumors. This review provides an overview on the value of radiomics in predicting response to treatment in patients with Gastrointestinal Tumors. Methods A systematic review was conducted, according to PRISMA guidelines. The protocol was prospectively registered (PROSPERO: CRD42019128408 ). PubMed, Embase, and Cochrane databases were searched. Original studies reporting on the value of radiomics in predicting response to treatment in patients with a Gastrointestinal Tumor were included. A narrative synthesis of results was conducted. Results were stratified by Tumor type. Quality assessment of included studies was performed, according to the radiomics quality score. Results The comprehensive literature search identified 1360 unique studies, of which 60 articles were included for analysis. In 37 studies, radiomics models and individual radiomic features showed good predictive performance for response to treatment (area under the curve or accuracy > 0.75). Various strategies to construct predictive models were used. Internal validation of predictive models was often performed, while the majority of studies lacked external validation. None of the studies reported predictive models implemented in clinical practice. Conclusion Radiomics is increasingly used to predict response to treatment in patients suffering from Gastrointestinal cancer. This review demonstrates its great potential to help predict response to treatment and improve patient selection and early adjustment of treatment strategy in a non-invasive manner.
